
    
      This is a randomized, prospective, placebo-controlled, double blind, repeated measures study.
      50 overweight/obese adults (body mas index > 27.5 kg/m2) will be recruited for participation
      and randomly assigned to one of two 12 week treatments: (1) daily oral administration of
      Dapagliflozin with dietary counseling to promote weight loss; or, (2) daily oral
      administration of a placebo with dietary counseling to promote weight loss.
    
  